Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study-Reference-Cited by-同舟云学术

Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study

Published:2024-02 Issue:10427 Volume:403 Page:645-656
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Ozen Ahmet,Chongsrisawat Voranush,Sefer Asena Pinar,Kolukisa Burcu,Jalbert Jessica J,Meagher Karoline A,Brackin Taylor,Feldman Hagit Baris,Baris Safa,Karakoc-Aydiner Elif,Ergelen Rabia,Fuss Ivan J,Moorman Heather,Suratannon Narissara,Suphapeetiporn Kanya,Perlee Lorah,Harari Olivier A,Yancopoulos George D,Lenardo Michael J,Miller Jutta L.,Eshach Adiv Orly,Bilgic Eltan Sevgi,Yorgun Altunbas Melek,Magliocco Mary,Matthews Helen,Marciano Beatriz E.,Chatchatee Pantipa,Trbovic Caryn F.,Burczynski Michael E.,Chaudhari Umesh,Usta Yusuf,Altuntaş Cansu,Yavuz Sibel,Baştürk Ahmet,Demirbaş Ar Fatma,Topal Erdem,Kalaycı Ayhan Gazi,Weerapakorn Wanlapa,Calabi Martínez Ana Andrea,Bottero Adriana

Funder

Division of Intramural Research

Regeneron Pharmaceuticals

National Institutes of Health

National Institute of Allergy and Infectious Diseases

Publisher

Elsevier BV

Reference26 articles.

1. CD55 deficiency, early-onset protein-losing enteropathy, and thrombosis;Ozen;N Engl J Med,2017

2. Decay-accelerating factor: biochemistry, molecular biology, and function;Lublin;Annu Rev Immunol,1989

3. Loss of CD55 in eculizumab-responsive protein-losing enteropathy;Kurolap;N Engl J Med,2017

4. Eculizumab-responsive adult onset protein losing enteropathy, caused by germline CD55-deficiency and complicated by aggressive angiosarcoma;Hagin;J Clin Immunol,2021

5. Broadly effective metabolic and immune recovery with C5 inhibition in CHAPLE disease;Ozen;Nat Immunol,2021

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complement‐targeted therapeutics: Are we there yet, or just getting started?;European Journal of Immunology;2024-09-12

2. Pozelimab for CHAPLE disease: results from in-trial interviews and clinical outcome assessments;Orphanet Journal of Rare Diseases;2024-08-08

3. Local complement activation and modulation in mucosal immunity;Mucosal Immunology;2024-08

4. Pharmacotherapy for CD55 deficiency with CHAPLE disease: how close are we to a cure?;Expert Opinion on Pharmacotherapy;2024-07-23

5. Immunologists’ Perspectives on Monogenic Inflammatory Bowel Diseases;Turkish Journal of Immunology;2024-04-18